Blog

Company News

Industry Trends

Laws Regulations

All Categories >

21

2023-07

Exhibition Invitation | Hycells Biotechnology Invites You to Attend IBI EXPO 2023, the International Bio-Innovative Drug Industry Conference

Shanghai Hycells Biotechnology Co., Ltd. was founded in 2021. With many years of deep expertise in cell therapy and gene therapy, the company is an innovative biotech firm primarily focused on delivering products and services in these fields. Its core business encompasses the collection and application of human immune cells, along with supporting biological reagents. Grounded in high-standard clinical sample collection and testing services, the company integrates biological sample management with translational medicine research to provide specialized in vitro and in vivo drug evaluation models and services for the development of innovative pharmaceuticals. Adhering to the core values of talent-driven excellence, quality-first principles, and innovation as the foundation, the company leverages technological innovation to continuously enhance the quality of clinical biological sample collection, processing, and application, thereby setting new industry benchmarks for domestic substitution and laying a solid foundation for the advancement and global competitiveness of China’s innovative drugs.

2023-07-21

He Yousheng

21

2023-07

Unafraid of Challenges, Bravely Moving Forward | Hycells Bio Celebrates Its 2nd Anniversary

June 30, 2023, marked the mid-year review day for the Hycells Initiative—and also coincided with the initiative’s second anniversary. To make the most of this special and meaningful occasion, the team decided to celebrate a little early. Two years may seem like but a fleeting moment in the grand sweep of history, yet for Hycells, those two years have been extraordinarily precious and truly unique.

2023-07-21

He Yousheng

03

2023-07

Hycells Biotechnology | A New Option for RCL Testing Platforms

According to the recently issued “Technical Guidance Principles for Pharmaceutical Research and Evaluation of In Vitro Gene Modification Systems (Trial)”, RCL testing is critical as a safety assessment step throughout the research, development, and manufacturing of cell-based therapeutics.

2023-07-03

He Yousheng

19

2023-06

On the Dragon Boat Festival, let’s celebrate fatherly love!

Following the recent celebrations for the Goddess of Harmony and Blessings Day and Mother’s Day, the long-awaited Father’s Day has finally arrived for our male colleagues at Hycells. Chinese cultural tradition has always emphasized restraint and silence, advocating that profound love is often best expressed without words. On this auspicious occasion of the Dragon Boat Festival, let us take a moment to openly acknowledge and celebrate the deep, unwavering love of fathers.

2023-06-19

He Yousheng

13

2023-06

Hycells Biotechnology Obtains ISO 9001:2015 Quality Management System Certification

On June 8, 2023, Shanghai Hycells Biotechnology Co., Ltd. officially obtained the GB/T 19001-2016/ISO 9001:2015 Quality Management System Certification, marking a new milestone in the company’s standardized, regulated, and scientifically managed quality assurance practices.

2023-06-13

He Yousheng

19

2023-04

Pharmaceutical Source Workshop, Session 2 | Antibody Discovery and Drug-likeness Analysis

Focusing on the fields of biomacromolecules, cell therapy, and gene therapy, this program takes a comprehensive, end-to-end approach to drug discovery and development, addressing key challenges and bottlenecks throughout the entire R&D process. It features carefully designed knowledge modules and invites industry experts to deliver small-scale, in-person presentations, making it a truly focused platform for technical exchange and interaction. This course is designed to provide professionals in the field with a new, on-the-job platform for in-depth learning.

2023-04-19

He Yousheng
< 1...15161718 >